Greg Cima

Articles Authored by Greg Cima
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.
Revvity Sees Possible Path to Higher Growth Rates in 2025 While Firm's Q4 Dx Revenues Rise 4 Percent
Premium
The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.
The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.
The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess the risk that patients will develop severe illness.

The University of Michigan's MyHPVscore test uses Bio-Rad's Droplet Digital PCR assay technology to detect HPV DNA fragments that are released by tumor cells.
Through Agency-Funded Contractors, NIAID Aims to Help Bring Infectious Disease Tests to Market
Premium
The Diagnostics Development Services program is, so far, being used to help point-of-care testing firm Fluxergy bring to market a test for sexually transmitted infections.
The company also said that its Diagnostics and Genomics revenues were down 1 percent during fiscal Q4, although its overall revenues were up slightly.
Hologic Revenues Rise 5 Percent on Strength of Molecular Diagnostics Business
The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.
China Instrument Sales Drag on Revvity Life Science Segment as Company Q3 Revenues Rise 2 Percent
Premium
Similar to other firms, the firm said that it has been negatively impacted as customers in China wait for government stimulus funding to arrive.
Endometriosis is associated with debilitating pain and increased risk of cancer and autoimmune diseases, yet diagnosis remains out of reach for many patients.
